Harnessing the vulnerabilities of p53 mutants in lung cancer – Focusing on the proteasome: a new trick for an old foe?

References

• World Health Organization. Cancer. [accessed 2019 July 13]. https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, RA O, BW B, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. doi:10.1056/NEJMoa040938.
   PubMed Web of Science ®Google Scholar
• Nasim F, BF S, GA E. 2019. Lung cancer. Med Clin North Am. 103:463–473. doi:10.1016/j.mcna.2018.12.006.
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Brahmer JR. 2015. Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 21:976–984. doi:10.1158/1078-0432.CCR-14-1187.
   PubMed Web of Science ®Google Scholar
• Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–1110. doi:10.1038/ng.2396.
   PubMed Web of Science ®Google Scholar
• Shetzer Y, Molchadsky A, Rotter V. Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation. Cold Spring Harb Perspect Med. 2016;6;a026203. doi:10.1101/cshperspect.a026203.
   PubMed Web of Science ®Google Scholar
• Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2:a001107. doi:10.1101/cshperspect.a001107.
   PubMed Web of Science ®Google Scholar
• Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004:847–860. doi:10.1016/j.cell.2004.11.004.
   Google Scholar
• Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. 2015. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 523:352–356. doi:10.1038/nature14430.
   PubMed Web of Science ®Google Scholar
• Alexandrova EM, Mirza SA, Xu S, Schulz-Heddergott R, Marchenko ND, Moll UM. P53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis. 2017;8. doi:10.1038/cddis.2017.80.
   Web of Science ®Google Scholar
• National Institutes of Health. ClinicalTrials.gov. [accessed 2019 Oct 28]. https://clinicaltrials.gov/ct2/results?cond=apr+246&term=&cntry=&state=&city=&dist=&Search=Search.
   Google Scholar
• National Institutes of Health. ClinicalTrials.gov. [accessed 2019 Oct 28]. https://clinicaltrials.gov/ct2/results?cond=&term=hsp90+inhibitor&cntry=&state=&city=&dist=.
   Google Scholar
• Halasi M, Pandit B, Gartel AL. 2014. Proteasome inhibitors suppress the protein expression of mutant p53. Cell Cycle. 13:3202–3206. doi:10.4161/15384101.2014.950132.
   PubMed Web of Science ®Google Scholar
• An WG, Chuman Y, Fojo T, Blagosklonny MV. 1998. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res. 244:54–60. doi:10.1006/excr.1998.4193.
   PubMed Web of Science ®Google Scholar
• Choudhury S, Kolukula VK, Preet A, Albanese C, Avantaggiati ML. 2013. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle. 12:1022–1029. doi:10.4161/cc.24128.
   PubMed Web of Science ®Google Scholar
• Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909. doi:10.1038/ncb3380.
   PubMed Web of Science ®Google Scholar
• Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, et al. Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667. doi:10.1038/ncomms3667.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. 2002. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2:594–604. doi:10.1038/nrc864.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature. 408:307–310. doi:10.1038/35042675.
   PubMed Web of Science ®Google Scholar
• Lu H, Levine AJ. 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A. 92:5154–5158. doi:10.1073/pnas.92.11.5154.
   PubMed Web of Science ®Google Scholar
• Walker KK, Levine AJ. 2002. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci. 93:15335–15340. doi:10.1073/pnas.93.26.15335.
   Google Scholar
• Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2. doi:10.1101/cshperspect.a000919.
   Web of Science ®Google Scholar
• Chène P. 2001. The role of tetramerization in p53 function. Oncogene. 20:2611–2617. doi:10.1038/sj.onc.1204373.
   PubMed Web of Science ®Google Scholar
• Weinberg RL, Freund SMV, Veprintsev DB, Bycroft M, Fersht AR. Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol. 2004;342:801–811. doi:10.1016/j.jmb.2004.07.042.
   PubMed Web of Science ®Google Scholar
• Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362:857–860. doi:10.1038/362857a0.
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992. doi:10.1016/0092-8674:90644-R
   PubMed Web of Science ®Google Scholar
• Grossman SR, Deato ME, Brignone C. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003;300:342–344. doi:10.1126/science.1080386.
   PubMed Web of Science ®Google Scholar
• Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao Z-X, Kumar S, Howley PM, Livingston DM. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 2:405–415. doi:10.1016/S1097-2765(00)80140-9.
   PubMed Web of Science ®Google Scholar
• Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, Hupp TR. 2015. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser 20 and Thr 18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J. 342:133–141. doi:10.1042/bj3420133.
   Google Scholar
• Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 268:2764–2772. doi:10.1046/j.1432-1327.2001.0222x.
   PubMedGoogle Scholar
• Ou YH, Chung PH, Sun TP, SS Y. 2005. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-Terminal acetylation. Mol Biol Cell. 16:1684–1695. doi:10.1091/mbc.e04-08-0689.
   PubMed Web of Science ®Google Scholar
• Yogosawa S, Yoshida K. 2018. Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis. Cancer Sci. 109:3376–3382. doi:10.1111/cas.13792.
   PubMed Web of Science ®Google Scholar
• Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. 1999. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A. 96:13777–13782. doi:10.1073/pnas.96.24.13777.
   PubMed Web of Science ®Google Scholar
• Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:325–334. doi:10.1016/S00928674(00)80416-X.
   PubMed Web of Science ®Google Scholar
• Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. 1998. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem. 273:33048–33053. doi:10.1074/jbc.273.49.33048.
   PubMed Web of Science ®Google Scholar
• Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao T-P. 2001. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. Embo J. 20:1331–1340. doi:10.1093/emboj/20.6.1331.
   PubMed Web of Science ®Google Scholar
• Laptenko O, Prives C. 2006. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13:951–996. doi:10.1038/sj.cdd.4401916.
   PubMed Web of Science ®Google Scholar
• Harris SL, Levine AJ. 2005. The p53 pathway: positive and negative feedback loops. Oncogene. 23:2899–2908. doi:10.1038/sj.onc.1208615.
   Google Scholar
• Wasylishen AR, Lozano G. Attenuating the p53 pathway in human cancers: many means to the same end. Cold Spring Harb Perspect Med. 2016;6. doi:10.1101/cshperspect.a026211.
   Web of Science ®Google Scholar
• Lukashchuk N, Vousden KH. 2007. Ubiquitination and degradation of Mutant p53. Mol Cell Biol. 27:8284–8295. doi:10.1128/mcb.00050-07.
   PubMed Web of Science ®Google Scholar
• Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM. 2011. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 9:577–588. doi:10.1158/1541-7786.mcr-10-0534.
   PubMed Web of Science ®Google Scholar
• Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. 2006. MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin. J Biol Chem. 281:33030–33035. doi:10.1074/jbc.C600147200.
   PubMed Web of Science ®Google Scholar
• Shvarts A, Bazuine M, Dekker P, Ramos YFM, Steegenga WT, Merckx G, RCA VH, van der Houven van Oordt W, van der Eb AJ, AG J, et al. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics. 1997;43:34–42. doi:10.1006/geno.1997.4775.
   PubMed Web of Science ®Google Scholar
• Hoffman Y, Pilpel Y, MicroRNAs OM. 2014. Alu elements in the p53-Mdm2-Mdm4 regulatory network. J Mol Cell Biol. 6:192–197. doi:10.1093/jmcb/mju020.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee JH, Ha M, Nam JW, Kim VN. 2009. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol. 16:23–29. doi:10.1038/nsmb.1533.
   PubMed Web of Science ®Google Scholar
• Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 2011;10. doi:10.1186/1476-4598-10-29.
   PubMed Web of Science ®Google Scholar
• Suh -S-S, Yoo JY, Nuovo GJ, Jeon Y-J, Kim S, Lee TJ, Kim T, Bakacs A, RH A, Kaur B, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci. 2012;109:5316–5321. doi:10.1073/pnas.1202465109.
   PubMed Web of Science ®Google Scholar
• Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–6650.
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Curtis C. Human Cancers. Science. 1991;253:49–53. doi:10.1126/science.1905840.
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. 2010. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 1:a001008. doi:10.1101/cshperspect.a001008.
   Google Scholar
• Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. doi:10.1002/humu.10081.
   PubMed Web of Science ®Google Scholar
• Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP. 2001. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 18:705–719. doi:10.1183/09031936.01.00062201.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clinical Cancer Res. 2000;6:4055–4063.
   PubMed Web of Science ®Google Scholar
• Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S, Liu B. TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: evidence from a meta-analysis. Molecular and Clinical Oncology. 2016;5:705–713. doi:doi.10.3892/mco.2016.1057.
   PubMed Web of Science ®Google Scholar
• Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C. 2008. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thoracic Cardiovasc Surg. 135:1036–1041. doi:10.1016/j.jtcvs.2007.10.072.
   PubMed Web of Science ®Google Scholar
• Campling BG, El-Deiry WS. 2003. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol. 24:141–156. doi:10.1385/MB:24:2:141.
   PubMed Web of Science ®Google Scholar
• Ciechanover A. 2005. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 6:79–86. doi:10.1038/nrm1552.
   PubMed Web of Science ®Google Scholar
• Recognition FD. 2009. Processing of Ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 78:477–513. doi:10.1146/annurev.biochem.78.081507.101607.
   PubMed Web of Science ®Google Scholar
• Pickart CM, Cohen RE. 2004. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol. 5:177–187. doi:10.1038/nrm1336.
   PubMed Web of Science ®Google Scholar
• Vaughan CA, Pearsall I, Singh S, Windle B, Deb SP, Grossman SR, Yeudall WA, Deb S. 2016. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget. 7:12426–12446. doi:10.18632/oncotarget.6998.
   PubMedGoogle Scholar
• Kubbutat MHG, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature. 387:299–303. doi:10.1038/387299a0.
   PubMed Web of Science ®Google Scholar
• Kubbutat MHG, Ludwig RL, Ashcroft M, Vousden KH. 2015. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol. 18:5690–5698. doi:10.1128/mcb.18.10.5690.
   Google Scholar
• Joerger AC, Fersht AR. 2007. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene. 26:2226–2242. doi:10.1038/sj.onc.1210291.
   PubMed Web of Science ®Google Scholar
• Midgley CA, Lane DP. 1997. P53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1179–1189. doi:10.1038/sj.onc.1201459.
   PubMed Web of Science ®Google Scholar
• Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, Ronai Z. 2000. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol. 295:1009–1021. doi:10.1006/jmbi.1999.3387.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Saliba D, Wallace M, Finlan L, PRR L-S, Hupp TR. 2006. Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J. 397:355–367. doi:10.1042/bj20051521.
   PubMed Web of Science ®Google Scholar
• Prives C, White E. 2008. Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev. 22:1259–1264. doi:10.1101/gad.1680508.
   PubMed Web of Science ®Google Scholar
• Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8(531–539):PMC363177. doi:10.1128/MCB.8.2.531.
   Google Scholar
• Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. 2015. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol. 18:1517–1524. doi:10.1128/mcb.18.3.1517.
   Google Scholar
• Peng Y, Chen L, Li C, Lu W, Chen J. 2001. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem. 276:40583–40590. doi:10.1074/jbc.M102817200.
   PubMed Web of Science ®Google Scholar
• Schulz-Heddergott R, Moll UM. 2018. Gain-of-function (GOF) mutant p53 as actionable therapeutic target. Cancers (Basel). 10:1–16. doi:10.3390/cancers10060188.
   Web of Science ®Google Scholar
• Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. 2008. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 27:3371–3383. doi:10.1038/sj.onc.1211010.
   PubMed Web of Science ®Google Scholar
• Esser C, Scheffner M, Höhfeld J. 2005. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem. 280:27443–27448. doi:10.1074/jbc.M501574200.
   PubMed Web of Science ®Google Scholar
• Frum RA, Love IM, Damle PK, Mukhopadhyay ND, Palit Deb S, Deb S, Grossman SR. 2016. Constitutive activation of DNA damage checkpoint signaling contributes to mutant p53 accumulation via modulation of p53 ubiquitination. Mol Cancer Res. 14:423–436. doi:10.1158/1541-7786.mcr-15-0363.
   PubMed Web of Science ®Google Scholar
• Lisek K, Walerych D, Del Sal G. 2017. Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer. Mol Cell Oncol. 4:e1217967. doi:10.1080/23723556.2016.1217967.
   PubMed Web of Science ®Google Scholar
• Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. 2004. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 54:343–353. doi:10.1007/s00280-004-0811-4.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. 2004. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci. 95:176–180. doi:10.1111/j.1349-7006.2004.tb03200.x.
   PubMed Web of Science ®Google Scholar
• Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP, Stabilizes B. 2019. Activates p53 in proliferative compartments of both normal and tumor tissues in vivo. Cancer Res. 79:3595–3607. doi:10.1158/0008-5472.CAN-18-3744.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. 2001. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 20:4519–4527. doi:10.1038/sj.onc.1204623.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto KI, Libermann TA, Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104–1112. doi:10.1182/blood.V87.3.1104.bloodjournal8731104.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A. 2002. Palombella V NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 277:16639–16647. doi:10.1074/jbc.M200360200.
   PubMed Web of Science ®Google Scholar
• Roy P, Sarkar UA, Basak S. 2018. The NF-κB activating pathways in multiple myeloma. Biomedicines. 6:59. doi:10.3390/biomedicines6020059.
   PubMed Web of Science ®Google Scholar
• Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010;1(1):59–68. doi:10.18632/oncotarget.109.
   PubMed Web of Science ®Google Scholar
• Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg. 2004;781207–781214. doi:10.1016/j.athoracsur.2004.04.029.
   Web of Science ®Google Scholar
• Ling Y, Liebes L. Mechanisms of proteasome inhibitor PS-341-induced G 2 -M-Phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003;9:1145–1154.
   PubMed Web of Science ®Google Scholar
• Schenkein DP. Preclinical data with bortezomib in lung cancer. Clin Lung Cancer. 2005;7(Suppl 2):S49–55. doi:10.3816/CLC.2005.s.008.
   PubMedGoogle Scholar
• Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer theraapy. Clin Cancer Res. 1999;5:2638–2645.
   PubMed Web of Science ®Google Scholar
• Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–1428.
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005;5:18. Published 2005 Jun 1. doi:10.1186/1475-2867-5-18.
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–2622.
   PubMed Web of Science ®Google Scholar
• Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000;6:3719–3728.
   PubMed Web of Science ®Google Scholar
• Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341(Velcade) into the therapeutic approach to. Lung Cancer. Lung Cancer. 2003;41(suppl1):S89–S9. doi:10.1016/S0169-5002(03)00149-1.
   PubMedGoogle Scholar
• Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. 2007. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2:1112–1116. doi:10.1097/JTO.0b013e31815ba7d0.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. 2009. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 100:1379–1384. doi:10.1038/sj.bjc.6605043.
   PubMed Web of Science ®Google Scholar
• Bommakanti SV, Dudek AZ, Khatri A, Kirstein MN, Gada PD. 2011. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. Am J Clin Oncol Cancer Clin Trials. 34:597–602. doi:10.1097/COC.0b013e3181f9441f.
   PubMed Web of Science ®Google Scholar
• Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G. 2007. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res. 13:3642–3651. doi:10.1158/1078-0432.CCR-07-0061.
   PubMed Web of Science ®Google Scholar
• Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, Rehm PK, Olazagasti J, Kozower BD, Bao Y. 2012. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol. 7:1683–1690. doi:10.1097/JTO.0b013e318267928d.
   PubMed Web of Science ®Google Scholar
• Millward M, Price T, Townsend A, Sweeney C, Spenser A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30:2303–2317. doi:10.1007/s10637-011-9766-6.
   PubMed Web of Science ®Google Scholar
• Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribiero M. 2006. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 24:5025–5033. doi:10.1200/JCO.2006.06.1853.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, WL T, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009;4:1002–1009. doi:10.1097/JTO.0b013e3181aba89f.
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. 2009. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 27:4487–4491. doi:10.1200/JCO.2009.22.7066.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K. 2010. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer. 68:420–426. doi:10.1016/j.lungcan.2009.07.011.
   PubMed Web of Science ®Google Scholar
• Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DHM, Koczywas M, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A california cancer consortium trial. Clin Lung Cancer. 2011;12:33–37. doi:10.3816/CLC.2011.n.004.
   PubMed Web of Science ®Google Scholar
• Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, KR O, JH B, Robinson EG, Ahuja HG, Kirschling RJ, et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: A wisconsin oncology network phase II study. Invest New Drugs. 2014;32:195–199. doi:10.1007/s10637-013-9980-5.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, et al. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015;10:172–180. doi:10.1097/JTO.0000000000000383.
   PubMed Web of Science ®Google Scholar
• Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, et al. A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2016;77:949–956. doi:10.1007/s00280-016-2997-7.
   PubMed Web of Science ®Google Scholar
• Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR. 2009. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II southwest oncology group study (S0339). J Thorac Oncol. 4:87–92. doi:10.1097/JTO.0b013e3181915052.
   PubMed Web of Science ®Google Scholar
• Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R. 2012. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 7:1032–1040. doi:10.1097/JTO.0b013e31824de2fa.
   PubMed Web of Science ®Google Scholar
• Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R. 2010. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer. 68:89–93. doi:10.1016/j.lungcan.2009.05.009.
   PubMed Web of Science ®Google Scholar
• Besse B, Planchard D, Veillard A-S, Taillade L, Khayat D, Ducourtieux M, Pignon J-P, Lumbroso J, Lafontaine C, Mathiot C, et al. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer. 2012;76:78–83. doi:10.1016/j.lungcan.2011.09.006.
   PubMed Web of Science ®Google Scholar
• Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest oncology group phase II trial (S0327). J Thorac Oncol. 2006;1:996–1001. doi:10.1097/01243894-200611000-00013.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, et al. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: A California cancer consortium phase II study (NCI 7003). J Thorac Oncol. 2011;6:1741–1745. doi:10.1097/JTO.0b013e318225924c.
   PubMed Web of Science ®Google Scholar
• Drilon A, Schoenfeld AJ, Arbour KC. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harb Mol Case Stud. 2019;5. doi:10.1101/mcs.a003665.
   Web of Science ®Google Scholar
• Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE, Wang Z, Lee S, et al. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72:861–868. doi:10.1007/s00280-013-2267-x.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Clinical Trials.Gov. [accessed 2019 Jun 12]. https://clinicaltrials.gov/ct2/results?cond=Lung+Cancer&term=Carfilzomib&cntry=&state=&city=&dist=.
   Google Scholar
• Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol. 1999 Oct;30:1221–1225. doi:10.1016/s0046-8177(99)90041-2.
   PubMed Web of Science ®Google Scholar